Krystal Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Krystal Biotech, Inc. (KRYS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 0 shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2024-02-26
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-03-31 was 0.00 shares.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 13.75K shares, a 378.30% increase from fiscal 2021.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2021 was 2.88K shares.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2020 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | 0.00 shares derived: sum of 2 quarters · filed 2024-02-26 | 0.00 shares derived: sum of 3 quarters · filed 2024-02-26 | 0.00 shares 10-K · filed 2024-02-26 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-06 | 0.00 shares 10-Q · filed 2023-11-06 | 8.75K shares derived: sum of 4 quarters · filed 2024-02-26 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 0.00 shares 10-Q · filed 2023-08-07 | 8.75K shares derived: sum of 3 quarters · filed 2024-02-26 | 12.88K shares derived: sum of 4 quarters · filed 2024-02-26 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-08 | 8.75K shares derived: sum of 2 quarters · filed 2024-02-26 | 12.88K shares derived: sum of 3 quarters · filed 2024-02-26 | 13.75K shares derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-12-31 | 8.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | 12.88K shares derived: sum of 2 quarters · filed 2024-02-26 | 13.75K shares derived: sum of 3 quarters · filed 2024-02-26 | 13.75K shares 10-K · filed 2024-02-26 |
| 2022-09-30 | 4.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 5.00K shares derived: sum of 2 quarters · filed 2022-11-07 | 5.00K shares 10-Q · filed 2022-11-07 | 5.38K shares derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-06-30 | 876.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 876.00 shares 10-Q · filed 2022-08-08 | 1.25K shares derived: sum of 3 quarters · filed 2023-02-27 | |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-09 | 375.00 shares derived: sum of 2 quarters · filed 2023-02-27 | ||
| 2021-12-31 | 375.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 2.88K shares 10-K · filed 2023-02-27 | ||
| 2021-09-30 | 2.50K shares 10-Q · filed 2021-11-08 | |||
| 2020-12-31 | 0.00 shares 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |